All News

early.ra_.2.jpg

Predicting Inflammatory Arthritis in At-Risk Persons

Jack Cush, MD

The Annals of Internal Medicine has published a predictive score to distinguish low-risk from high-risk inflammatory arthritis (IA) and who may benefit from risk stratification and preventive measures.

Read Article
JIA.oligoarticular.jpg

MMWR: Arthritis Among Children and Adolescents

Jack Cush, MD

The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021.

Read Article
RheumNow Podcast square

"Ask Cush Anything" Returns (7.21.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything"

Read Article
Xeljanz4.jpg

Tofactitinib in PsA & RA: Nine Year Safety Data

Jack Cush, MD

Tofacitinib is FDA approved for psoriatic arthritis and rheumatoid arthritis, but long term safety outcomes beyond a year are limited. A real-world, post-marketing surveillance of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified.

Read Article
vaccination.jpg

Hold the Methotrexate for One Week

Jack Cush, MD

In 2018, Park et al showed optimal responses to influenza vaccination in RA patients was best achieved by holding methotrexate for 2 weeks following immunization, with improved humoral responses. Now, a followup trial suggests that equivalent results are had by holding MTX for only 1 week with the "flu" vaccine.

Read Article
RheumNow Podcast square

Anti-Drug Antibodies with Biologics (7.14.2023)

Jack Cush, MD

Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!

Read Article
EMA's CHMP adopted a positive opinion for 1st tocilizumab biosimilar, Tyenne® (from Fresenius Kab), for Rx of RA, systemic JIA, poly JIA, GCA, COVID-19 and CAR-T cell-induced cytokine release syndrome. No decision yet on IL6 biosimilar in USA https://t.co/w00yGfm3Vv https://t.co/UzxPvBf1nG

Links:

Dr. John Cush RheumNow ( View Tweet)
Tofactitinib in PsA & RA: Nine Year Safety Data A real-world, post-marketing surveillance (PMS) of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified. https://t.co/nVglUz6FJC https://t.co/t3dI5SzjJa

Links:

Dr. John Cush RheumNow ( View Tweet)
Combination Cannabidiol (CBD) & hydroxychloroquine in RA? A phase II trial of IHL-675A (CBD+HCQ) will soon begin; following on phase I and animal studies showing it was tolerated, with no adverse events of concern.IHL-675A was superior to HCQ alone. https://t.co/H90D9LzNSo https://t.co/JiS6HL38Jg

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/vGt12ul6iy https://t.co/044BScmSYc

Links:

Dr. John Cush RheumNow ( View Tweet)
US claims data shows the incidence rate of Herpes zoster (HZ) to be higher in RA (21.5/1000PY;HR 1.93) than non-RA (7.6/1000PY), increasing with age in RA,≥ 65 yrs -23.4/1000PY), highest w/ steroids and JAK inhibitors https://t.co/yH5bRGEyFh https://t.co/avvHwPkvJB

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of >19K RA pts in National Databank showed that Opioids vs NSAID use had similar MACE risk(20.6 vs 18.9/1000 PY), but opioids had higher mortality (13.5 vs 10.8/1000 PY; HR1.33) & VTE risk(HR=1.41). Opioids are not safer than NSAIDs https://t.co/J56BqYMKM1 https://t.co/xiz4GGUnJC

Links:

Dr. John Cush RheumNow ( View Tweet)
Combination Cannabidiol (CBD) & hydroxychloroquine in RA? A phase II trial of IHL-675A (CBD+HCQ) will soon begin; following on phase I and animal studies showing it was tolerated, with no adverse events of concern.IHL-675A was superior to HCQ alone. https://t.co/HZYR7FA7i1 https://t.co/jvlot0OIw4

Links:

Dr. John Cush RheumNow ( View Tweet)
Nonprofit Allen Institute for Immunology will partner with researchers from Eli Lilly to investigate and profile disease state diversity and biomarkers for drug response in atopic dermatitis and rheumatoid arthritis https://t.co/nRbdWdFx7C https://t.co/rlngbtxgUo

Links:

Dr. John Cush RheumNow ( View Tweet)
In AUSTRALIA, 30% (~ 7million) have a chronic #MSK condition, costing $14.6 billion (10% of all healthcare spending) in 2019-20. Overall, 4 million w/ back problems, 3 million arthritis, 900,000 osteoporosis, 450,000 w/ #RA. https://t.co/TDV50PoRXj https://t.co/EtSUuv6jMA

Links:

Dr. John Cush RheumNow ( View Tweet)
Filgotinib Effects on Semen and Sex Hormones The oral Janus kinase 1 inhibitor filgotinib is available worldwide, but not in the USA, where the FDA held up its approval for use in RA due to unfinished studies of filgotinib's effects on sperm cells. https://t.co/SrwInSY45G https://t.co/TD54PXNFbi

Links:

Dr. John Cush RheumNow ( View Tweet)
Pre-Clinical RA - Clinical Trial Outcomes https://t.co/EIG1eam31h https://t.co/6rYcGmgJG5

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read review of clinical trials in CTD-ILD, specifically looking at: - Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes - Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant https://t.co/HyCsrzejLU https://t.co/ejJKOtXupC

Links:

Dr. John Cush RheumNow ( View Tweet)
Biologics Keep Early RA in Check for at Least One Year Treatment with at least some biologic drugs significantly reduced 1-year progression of early rheumatoid arthritis (RA) relative to classical small-molecule agents, researchers reported. https://t.co/FBFX53lZfp https://t.co/l1RapKWlFk

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: RA Disease Activity and Alcohol Use https://t.co/tXuAJ4GRl4 https://t.co/3ieVw8BcIs

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×